Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Sees Large Growth in Short Interest

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) was the recipient of a significant growth in short interest in September. As of September 30th, there was short interest totalling 108,300 shares, a growth of 192.7% from the September 15th total of 37,000 shares. Based on an average daily trading volume, of 222,700 shares, the short-interest ratio is presently 0.5 days. Currently, 0.4% of the company’s stock are sold short.

Coeptis Therapeutics Stock Performance

Coeptis Therapeutics stock opened at $0.18 on Friday. Coeptis Therapeutics has a 1-year low of $0.15 and a 1-year high of $1.38. The firm has a market capitalization of $6.64 million, a price-to-earnings ratio of -0.34 and a beta of -0.91. The firm’s fifty day moving average price is $0.19 and its two-hundred day moving average price is $0.27.

Coeptis Therapeutics (NASDAQ:COEP) last released its quarterly earnings data on Friday, August 16th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01. On average, research analysts forecast that Coeptis Therapeutics will post -0.26 EPS for the current year.

Analysts Set New Price Targets

Separately, LADENBURG THALM/SH SH lowered shares of Coeptis Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 18th.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.